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Human monoclonal antibodiesSARS-CoV causes an acute infection making targeted passive immunotherapy an attractive treatment
strategy. We previously generated human mAbs speciﬁc to the S1 region of SARS-CoV S protein. These mAbs
bind epitopes within the receptor binding domain (RBD) or upstream of the RBD. We show that mAbs
recognizing epitopes within the RBD inhibit infection by preventing viral attachment to the cellular receptor.
One mAb binds upstream of the RBD and prevents viral entry by inhibiting a post-binding event. Evaluation
of several mAbs demonstrated varying ability of the mAbs to select escape mutants when used individually.
However, a mixture of antibodies could effectively neutralize a range of mutant viruses. These data strongly
suggest that a mixture containing antibodies recognizing distinct regions and targeting more than one step
in viral entry is likely to be more effective in neutralizing the virus and suppressing the generation of escape
mutants, and thus potentially constitute a highly effective passive immunotherapy.
© 2009 Elsevier Inc. All rights reserved.Introduction
Increasingly, RNA viruses appear to be responsible causal agents
of newly emerging infections (Duffy et al., 2008; Holmes, 2004;
Lai, 2003; Osterhaus, 2008). Severe acute respiratory syndrome-
coronavirus (SARS-CoV) is one such emergent infection. Unlike other
newly emerged zoonotic infections, SARS-CoV gained the ability to
spread efﬁciently from human to human resulting in a worldwide
outbreak (Osterhaus 2008). SARS-CoV causes severe respiratory
disease in humans resulting in respiratory distress that requires
ventilation support in approximately 20% of infected individuals
(Knudsen et al., 2003; Peiris et al., 2004). The global outbreak of SARS-
CoV resulted in over 8000 infections worldwide in 2002–2003 (Baker,
2004; Knudsen et al., 2003; Ksizek et al., 2003; Kuiken et al., 2003;
Marra et al., 2003). Although, such an outbreak has not recurred, the
presence of SARS-CoV in environmental reservoirs remains a threat to
human health (Lau et al., 2005; Li et al., 2005; Normile, 2005).
Therefore, it is important to establish therapeutic interventions
against this potentially life threatening infection.
SARS-CoV causes an acute infection and therefore therapies that
offer instantaneous protection are likely to be most effective. APrevention, Measles, Mumps,
ton Rd., Mailstop C22, Atlanta,
ll rights reserved.number of therapeutic strategies such as inhibition of viral entry, viral
replication, and viral maturation have been investigated (Golda and
Pyrc, 2008; Osterhaus, 2008). Amongst these, inhibition of viral entry
is particularly attractive since it will protect target cells from infection
thereby reducing the viral load, and allowing the host immune system
sufﬁcient time to mount an effective immune response and clear the
virus.
The SARS-CoV, mediates viral entry through the S protein. Unlike
human CoV-229E, the S protein of SARS-CoV is not cleaved into S1 and
S2 domains (Rota et al., 2003). However, it has a distinct S1 domain
that mediates receptor binding. The 318–510 amino acid region
within S1 represents the receptor binding domain (RBD) that inter-
acts with the cellular receptor, angiotensin-converting enzyme 2
(ACE2) (Li et al., 2005; Li et al., 2003; Wong et al., 2004). The S2
domain mediates fusion between the viral and host membranes
(Ksiazek et al., 2003) that is required for releasing the viral genome
into the cell (Ingallinella et al., 2004; Li et al., 2005; Li et al., 2003; Rota
et al., 2003; Tripet et al., 2004; Wong et al., 2004). Since both binding
and fusion events are mediated through the S protein, mAbs that
recognize the S protein may inhibit either of these steps.
Previously, we generated a large panel of human monoclonal
antibodies using B cells from XenoMouse® immunized with SARS-CoV
S protein (Coughlin et al., 2007). We identiﬁed several epitopes
recognized by S1 speciﬁc mAbs and found that a majority of these
neutralizing antibodies can react with the RBD. The RBD speciﬁc
antibodies were designated as group 1 based on epitope mapping and
further subgrouped based on the antibody complementary deter-
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We demonstrate that the group 1 monoclonal antibodies (mAbs)
neutralize SARS-CoV by preventing association of S protein with the
receptor on the surface of the target cells. Regions upstream of the
RBD in S1 as well as epitopes within the S2 domain (Coughlin et al.,
2007; Duan et al., 2005; Huang et al., 2006; Keng et al., 2005)
can also elicit neutralizing antibodies. In this context, we identiﬁed
one mAb that binds upstream of the SARS-CoV RBD, between amino
acids 12 and 261 (Coughlin et al., 2007). We demonstrate that
this mAb neutralizes the virus by preventing a post-binding step in
viral entry. Furthermore, we show that combinations of antibodies are
more effective than individual antibodies in neutralizing the wild
type as well as mutant viruses selected in the presence of individual
mAbs. These data suggest that targeting more than one epitope and/
or step in the viral entry will likely confer better protection against
SARS-CoV.
Results
Inhibition of receptor binding by RBD speciﬁc mAbs using VeroE6 cells
We have previously produced human monoclonal antibodies
(mAbs) that effectively neutralize SARS-CoV infection by interacting
with two distinct regions within the S1 domain of the S protein
(Coughlin et al., 2007). In order to understand the underlying mecha-
nism of neutralization by these antibodies, we developed a receptor
binding inhibition assay using VeroE6 cells that naturally express the
ACE2 receptor on their surface (Li et al., 2003; Wong et al., 2004). The
recombinant S protein fragment represented by amino acids 12–510
carrying a human Fc tag (S12–510-Fc) was bound to the surface of
target cells at an optimal concentration. The maximal binding of the
recombinant protein was detected upon staining with a FITC con-
jugated anti-human IgG antibody using ﬂow cytometry. The S12–510-
Fc recombinant protein was pre-incubated with increasing concen-
trations of each of the 19 previously identiﬁed and characterized S1
speciﬁc mAbs (Coughlin et al., 2007) and binding of the protein in the
presence of the mAbs was determined and compared to the maximal
binding. The IC50 value for each mAb was determined by the inhibi-Table 1
Groupa mAb Binding
region
S binding
Inhibitionb
IC50
(μg/ml)c
1A1 4E2 RBD Y 5.31
1A1 4G2 RBD Y 4.78
1A1 6C1 RBD Y 4.81
1B1 3A7 RBD Y 1.17
1B1 5A7 RBD Y 4.94
1B1 5D3 RBD Y 1.9
1B1 5D6 RBD Y 3.17
1B1 6B8 RBD Y 3.27
1B2 4A10 RBD Y 6.12
1B2 5A5 RBD Y 6.79
1B2 3F3 RBD Y 2.31
1B2 6B5 RBD Y 2.02
1B2 6C2 RBD Y 3.53
1B3 5E4 RBD Y 2.13
1B4 3C7 RBD Y 4.28
1B4 6B1 RBD Y 4.08
1D 3H12 RBD Y 3.71
1Ed 1B5 RBD Y 2.84
2B1 4D4 12–261 N N/A
a mAb group determined previously based on ELISA reactivity and immunoglobulin
sequence data.
b Inhibition of binding of recombinant S protein 12–510-Fc to the surface of target
VeroE6 cells.
c IC50 values determined from inhibition curve of the mAb.
d mAb 1B5 was previously designated in group 2B2, upon further analysis of the
puriﬁed mAb 1B5 it was determined to be RBD speciﬁc mAb with a unique CDR3
sequence and added to group 1 with designation group 1E.tion curve generated with increasing concentrations of mAb (Table 1).
Cells alone, cells lacking the cellular receptor (PA-1), cells mixed
with non-ACE2 binding S12–327-Fc fragment, as well as isotype
control antibody were included as negative controls to determine
non-speciﬁc binding and non-speciﬁc inhibition. No non-speciﬁc
binding or non-speciﬁc inhibition occurred (Fig. 1A). Represen-
tative data obtained for group 1 neutralizing mAbs are shown in
Fig. 1A.
Maximum inhibition of binding was seen with the highest con-
centration of antibodies used (Fig. 1A). Although group 1 mAbs bind
within the RBD, based on their complimentary determining region 3
(CDR3) sequences they were grouped into various subgroups (e.g.
groups 1A1, 1B1, 1B2, 1B3, 1B4, 1D and 1E). These antibodies likely
recognize seven distinct epitopes within the RBD and all of them
were able to inhibit S12–510-Fc binding (Table 1). The mAbs alone
failed to bind signiﬁcantly to cells (data not shown). Eighteen of the
previously identiﬁed 19 anti-S1 mAbs efﬁciently prevented the
binding of S1 protein thereby indicating that the mechanism of
neutralization of SARS-CoV infection of VeroE6 cells by these
antibodies was primarily through the inhibition of virus attachment
(Table 1 and Fig. 1A).
The mAb that recognizes an epitope upstream of the RBD inhibits a
post-binding event
Limited epitope mapping previously identiﬁed a group 2 mAb
4D4 that binds upstream of the RBD (Table 1) (Coughlin et al.,
2007). Therefore, we further investigated the mechanism of action
of this unique mAb, 4D4. While the RBD speciﬁc mAb 1B5 could
inhibit receptor association of S12–510-Fc protein, the mAb 4D4
failed to block the interaction of this protein with the cellular re-
ceptor (Fig. 1B). In fact, the 4D4 antibody had a marginal enhancing
effect on the binding of the S12–510-Fc protein to the cell surface
(Fig. 1B).
Since mAb 4D4 could not inhibit binding of the S protein, the
ability of mAb 4D4 to disrupt a post-binding step in viral entry was
examined using pseudotyped virus that expressed the SARS-CoV S
protein on its surface (Huang et al., 2006; Simmons et al., 2004; Yang
et al., 2005a; Yi et al., 2005). The post-binding events were detected
by binding the pseudovirus to the surface of the target 293T/T17 cells
transiently transfected with ACE2 at 4 °C for 1 h, which allowed viral
attachment but not entry. Following binding of the pseudovirus, the
cells were treated with increasing concentrations of the 4D4 mAb and
further incubated at 37 °C overnight. The mAb 4D4 could efﬁciently
prevent viral entry into target cells when added post-pseudovirus
binding (Fig. 2). Furthermore, the post-binding inhibition seen
was signiﬁcantly greater than was observed when the mAb and
pseudovirus were preincubated prior to addition to the target cells
(P=0.01).
Combinations of mAbs can more efﬁciently inhibit pseudotyped
virus entry
Next, we investigated whether a mixture of antibodies that react
with distinct epitopes and neutralize the virus by different mechan-
isms can lead to greater inhibition. The mAb 4D4 was used in
combination with a representative RBD speciﬁc mAb from each group
(Coughlin et al., 2007). The use of anti-S1 mAb mixture consisting of
twomAbs, resulted in 10–30% greater inhibition of pseudotyped virus
entry than each of the mAbs tested alone (Fig. 3). The combinations of
mAb showed little to no inhibition of virus in which HIV core was
pseudotyped with the VSV G protein (HIV/VSV-G) (data not shown)
indicating the speciﬁcity of their action.
The 4D4 and 3C7 mAb combination resulted in the most drama-
tic inhibition as shown by a signiﬁcant additive effect at the two
highest concentrations of mAb used (P values=0.0049, 0.046,
Fig. 1. Themajority of the humanmonoclonal antibodies block receptor association. (A) Ability of RBD speciﬁc humanmAbs (group 1) to inhibit receptor association of S protein was
detected using a receptor binding inhibition assay. A representative member is shown for each group of mAbs. The recombinant S12–510-Fc protein was preincubated with
increasing dilutions of mAbs. The mixture was added to the target VeroE6 cells and the recombinant protein binding was detected by ﬂow cytometry following staining with an FITC-
labeled anti-human IgG. (B) Comparison of the ability of N-terminal speciﬁc mAb 4D4 with RBD speciﬁc mAb 1B5 to inhibit receptor association of S12–510-Fc protein. Inhibition of
receptor association was examined as described for the group 1 mAbs. Isotype: human IgG isotype control.
Fig. 2. Post-binding inhibition by mAb 4D4. Increasing concentrations of mAb 4D4were
incubated with HIV/S pseudotyped virus for 1 h at 37 °C and added to target cells in a
standard neutralization protocol. Alternatively, HIV/S pseudovirus was bound to target
cells at 4 °C for 1 h, and mAb 4D4 was added post-binding at increasing concentrations.
Pseudotype virus entry was measured by luciferase expression in target 293T/T17 cells
transiently expressing human ACE2. Statistical signiﬁcance was determined by Student
t-test.
41M.M. Coughlin et al. / Virology 394 (2009) 39–460.016) (Fig. 3). Another combination that consistently demonstrated
increased inhibition was 4D4 and 5D3 (P values=0.00045, 0.00031,
0.042, 0.019, 0.042, 0.0101) (Fig. 3). The combinations of mAbs
4A10, 5E4, or 3H12 with 4D4 demonstrated a signiﬁcant increase
in inhibition (P values of 4D4 individually compared to combination, or
other mAb used individually compared to combinations equal to
0.0011/0.014, 0.031/0.0404, and 0.0052/0.0062, respectively) when
compared to the inhibition seen when each antibody was tested alone
at the highest concentrations (Fig. 3). The mAb 1B5 did not show
enhanced inhibitionwhen used in combinationwith 4D4 as compared
to the inhibition seen when used individually (Fig. 3).
The cocktail containing 4D4 and 3C7 mAbs was further tested for
its ability to neutralize SARS-CoV (Urbani) viral infection of VeroE6
cells. Brieﬂy, 200TCID50 of SARS-CoV was preincubated with a
combination of mAbs 4D4 and 3C7 for 1 h at 37 °C. The virus/
antibody mixture was added to VeroE6 cells and cell viability was
measured 48 h later. Similar to the results obtained using pseudo-
typed virus, the combination of 4D4 and 3C7 resulted in signiﬁcantly
increased protection when 0.781 μg/ml or 0.391 μg/ml of antibody
was used (Fig. 4).
Fig. 3. Effects of combinations of anti-S1 RBD speciﬁc and 4D4mAbs on pseudotype virus entry. (A) A representative mAb from each groupwas mixed withmAb 4D4 at the indicated
concentrations and preincubated with pseudotyped virus. Entry was measured by luciferase expression 48 h post-infection in target 293T/T17 cells transiently expressing ACE2.
Statistical signiﬁcance was determined by Student t-test.
Table 2
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mAbs, and may be neutralized by other mAbs
Selection pressures most likely resulted in the genetic changes
observed during the outbreak of 2002–2003, which led to the
identiﬁcation of different strains of SARS-CoV (Meulen et al., 2006;
Rockx et al., 2007; Sui et al., 2004; Sui et al., 2005; Yang et al., 2005b).
Therefore, we tested the ability of eleven anti-S1mAbs to yield escape
mutants. Cultivation of virus in the presence of nine of the eleven
mAbs resulted in the emergence of escape mutants at different
passages. Passage of virus in the presence of 2EC50 of three of the
mAbs 3C7, 3H12, and 4D4 resulted in the emergence of escape virus
within the ﬁrst several passages (Table 2) perhaps because mutants
that could escape neutralization existed within the viral population or
mutation occurred early in the virus replication. The existence of
escapemutantswas conﬁrmed by growing the virus in the presence of
higher doses of the corresponding mAb, up to 8EC50 (Table 2). Other
mAbs (5D6, 4A10, 5A5, 5E4, 6B1, and 1B5) resulted in the generation
of escape mutants over several passages. Of these mAbs, all except for
mAb 4A10 resulted in escape virus observed only in the sub-
neutralizing concentration of 1EC50 (Table 2). Viruses grown in theFig. 4. CombinationmAbs 4D4 and 3C7 show enhanced inhibition of SARS-CoV (Urbani)
infection. The mAbs 4D4 and 3C7 were analyzed for their ability to neutralize SARS-CoV
(Urbani) infection in VeroE6 cells. The mAbs (alone or in combination) were
preincubated with 200TCID50 SARS-CoV (Urbani) at 37 °C for 1 h and added to
VeroE6 cells. Infection was measured by resulting cell death using the luciferase based
Cell TiterGlo assay. Error bars represent standard deviation between duplicates within
experiment.presence of either 6C1 or 6C2 did not yield escape mutants at any of
the concentrations throughout the nine passages, suggesting the
possible recognition of conserved/essential regions within the S1
domain by these antibodies (Table 2).
The ability of other mAbs to inhibit SARS-CoV 3C7 and 4D4 escape
variants (SARS-CoV 3C7 and SARS-CoV 4D4, respectively) that were
generated in early passages was analyzed using mAbs 3C7, 3H12, and
4D4. SARS-CoV 3C7 and SARS-CoV 4D4 could be effectively neutral-
ized by a mixture of mAbs consisting of 3H12, 4D4 and 3C7 (Figs. 5A
and B respectively). Interestingly, mAb 3H12 could moderately
neutralize SARS-CoV 3C7 and efﬁciently neutralize SARS-CoV 4D4
when used individually (data not shown). Similarly, the mAb 3C7 and
mAb 4D4 could efﬁciently neutralize SARS-CoV 4D4 and SARS-CoVSARS-CoV (Urbani) was passaged every 48 h in the presence of mAbs at concentrations
of 1, 1.5 and 2 EC50. The ability of the mAbs to generate escape mutants was
determined by CPE.
Fig. 5. Inhibition of SARS-CoV escape mutant virus. SARS-CoV escape mutants were
generated by serial passages of the virus in the presence of individual mAbs every 48 h.
The neutralizing ability of mAb combination was determined by analysis of cell viability
using the luciferase based Cell TiterGlo assay 48 h post-infection. (A) SARS-CoV 3C7was
used in a neutralization assay with 3H12 (group 1) and 4D4 (group 2) mAbs in
combination with 3C7. (B) SARS-CoV 4D4 was used in a neutralization assay with mAbs
3H12 and 3C7 (group 1) in combination with mAb 4D4. A single outlier, in both A and B,
is not included in the analysis.
43M.M. Coughlin et al. / Virology 394 (2009) 39–463C7, respectively (data not shown). In contrast, the escape variants
were not effectively neutralized by the respective mAbs used to
generate the variants (Fig. 5). These results showed that despite the
propensity of the virus to escape neutralization by some mAbs when
used individually, escape mutant viruses were effectively neutralized
by a mixture of those antibodies.
Discussion
In this study, we sought to understand the mechanisms of pre-
viously described (Coughlin et al., 2007) anti-S1 mAb mediated
neutralization of SARS-CoV, the propensity of a subset of mAbs to
generate escape mutants and the efﬁcacy of neutralization of escape
variants by a mixture of monoclonal antibodies.
As expected, the mechanism of neutralization by most of these
mAbs was the inhibition of receptor binding that prevented viral
attachment to the target cells. This observation is consistent with
that made by other investigators (Rockx et al., 2008; Sui et al., 2004).
The mAb, 4D4 that binds upstream of the RBD, between amino acids
12 and 261 had no signiﬁcant effect on viral attachment to the target
cells but inhibited a post-binding event and prevented viral entry.
Recently, a neutralizing antibody, nAb 256, generated from a non-
immune scFv library was also found not to inhibit RBD binding (Suiet al., 2008). However, unlike 4D4 this antibody recognizes an
epitope within the RBD. The nAb 256 was demonstrated to have a
broader ability to bind to S protein variants, albeit with weak
neutralizing ability (Sui et al., 2008). The mechanism of inhibition by
nAb 256 is not yet known, and the lower efﬁciency was likely a
consequence of selecting the antibody from a library generated using
non-immune cells. Therefore, nAb 256 may not have undergone
afﬁnity maturation that results from immunization. The mAb 4D4
described here is the ﬁrst example of an antibody that binds within
the N-terminus of the S protein and neutralizes SARS-CoV by
inhibiting a post-binding event necessary for viral entry.
Although the function of the N-terminal region of the S1 domain is
not clearly deﬁned, a role for this region inmediating dimerization of S
protein has been suggested (Tian et al., 2004; Xiao et al., 2004).
Additionally, deletion of the ﬁrst 103 amino acids of the S protein leads
to a loss of ability tomediate fusionwhile retaining ACE2 binding (Tian
et al., 2004; Xiao et al., 2003). The ability of mAb 4D4 to more
efﬁciently inhibit viral entry when added post virus binding suggests
that the S protein might undergo a conformational change following
binding to ACE2 leading to unmasking of the epitope recognized by the
4D4 antibody. These results support the notion that the N-terminus of
the S protein contributes to the conformational change required to
mediate fusion between the viral and host membranes. The S protein
cleavage within the endosome by cathepsin L is essential to initiate
fusion of the viral and endosomal membranes (Bosch et al., 2008;
Huang et al., 2006; Simmons et al., 2005). Cathepsin L can cleave at
amino acid 678 located within the junction of the S1 and S2 domains
(Bosch et al., 2008) of the S protein. Other studies have suggested that
a conformational change is necessary for the S protein cleavage by
cathepsin L (Simmons et al., 2005). Although deﬁnitive proof is yet to
be generated, it is possible that mAb 4D4 could prevent the
conformational change necessary for the S protein cleavage by
cathepsin. This speculation is supported by earlier demonstration of
the inhibition of the pH-dependent fusion process within the
endosome for both Inﬂuenza virus and West Nile virus by viral
neutralizing antibodies that do not block viral attachment (Imai et al.,
1998; Thompson et al., 2009). West Nile virus opsonized by a fusion
inhibitory antibody resulted in the retention of the virus in the
endosome and likely led to targeted destruction of the virus particle in
the lysosomal compartment of the cell (Thompson et al., 2009). These
studies suggest that mAbs which can speciﬁcally inhibit cathepsin
cleavage of speciﬁc viral glycoproteins may serve as novel therapies
against viruses including Ebola virus, reovirus, and human CoV-229E.
Similar to results obtained using combinationmAb therapy against
HBV and RSV, a combination of two mAbs targeting different epitopes
within the S1 protein of SARS-CoV also has additive effects (Marasco,
2007). Use of mAb 4D4 with another mAb (such as 3C7 or 5D3)
resulted in increased inhibition. It is important to note that the
combination of mAbs 4D4 and 3C7 conferred near complete protec-
tion at an antibody concentration of 0.781 μg/ml, while individual
antibodies required about 12.5 μg/ml (Fig. 4). This however is not true
for all mAb combinations such as mAbs 4D4 and 1B5. The mAb 1B5
was previously determined to bind upstream of the RBD, however,
subsequent analysis determined that the puriﬁed mAb 1B5 can in fact
bind to the RBD. Lack of synergistic effect indicated that themAbs 4D4
and 1B5 likely interact with closely positioned conformational epi-
topes and compete with each other for binding. Similarly, a combina-
tion of RBD speciﬁc mAbs conferred protection in senescent mice
against SARS-CoV challenge; however, the combination was no more
efﬁcient than when antibodies were administered individually
indicating that the antibodies were possibly competing for binding
to the same region (Rockx et al., 2008). These observations highlight
the importance of carefully selecting different mAbs to form a
therapeutic cocktail.
SARS-CoV is an RNA virus and therefore has a greater intrinsic
ability to generate escape mutants, conferred by the error prone RNA
44 M.M. Coughlin et al. / Virology 394 (2009) 39–46dependent RNA polymerase. Escape mutants were generated rapidly
in the presence of high concentrations of three mAbs suggesting
that within the viral population antigenic variants existed that
escaped mAb neutralization. Although several mAbs did not readily
give rise to escape mutants, the escape variants did appear in the
presence of suboptimal concentrations of mAbs. This suggested that
escape mutants were most likely generated in response to mAb
pressure. The escape mutants generated in this study have not yet
been sequenced; however, nucleic acid sequence of escape mutants
from other studies has revealed that a single point mutation can
confer resistance against the selecting antibody (Mitsuki et al., 2008;
Sui et al., 2008; ter Meulen et al., 2006). It would be interesting to
determine the three dimensional structures of S proteins frommutant
viruses and the antibodies used for their selection and relate how the
mutation induced change in the conformation of the protein affected
its binding to the selecting antibody.
Although virus grown in the presence of monoclonal antibody 3C7,
3H12, or 4D4, could rapidly yield escape mutants; a mixture of these
three of mAbs effectively neutralized the escape variants. The mAb
3H12 could neutralize both the SARS-CoV 3C7 and SARS-CoV 4D4
escape variants and conﬁrmed our previous ﬁnding that the 3H12
epitope is distinct from epitopes 3C7 and 4D4. Additionally, the 3C7
mAb could neutralize SARS-CoV 4D4, conﬁrming that these two
epitopes are also distinct (Coughlin et al., 2007). However, the
propensity of these antibodies to allow escape mutants to arise when
used alone precludes their individual therapeutic utility. An ideal
passive therapy should eliminate or minimize the appearance of
escape variants. In this context it is important to note that in the
presence of mAbs 6C1 and 6C2 escape mutants failed to arise suggest-
ing that changes in these epitopes might be detrimental to SARS-CoV.
Further examination of these epitopes may result in the identiﬁcation
of regions within the S protein that would likely be good candidates
for a subunit vaccine.
Although others have demonstrated the utility of mAb cocktails
consisting of antibodieswith a similarmechanismof action (Meulen et
al., 2006; Rockx et al., 2008; Rockx et al., 2007; Sui et al., 2005; Yang et
al., 2005b), the present study shows the utility of a cocktail of
antibodies not only with different binding speciﬁcities but also modes
of action. This type of cocktail is likely to neutralize a broader range of
variants thatmay be circulating in nature and suppress the appearance
of escape mutants of SARS-CoV when used therapeutically.
Materials and methods
SARS-CoV and cells
SARS-coronavirus (SARS-CoV) Urbani strain was obtained from
CDC. Virus was propagated in VeroE6 cells in MEM serum free
medium (SFM) containing L-glutamine (Gibco, Carlsband, CA). The
viral titer was determined by infecting 1.2×104 VeroE6 cells/well in a
96 well plate with serial 1:10 dilutions of SARS-CoV. After 48 h of
incubation at 37 °C in a 5%CO2 humidiﬁed incubator cells were eval-
uated for cytopathic effect (CPE). The TCID50 value was calculated by
the Reed–Muench method.
Escape virus was generated by serial passage of virus in the
presence of various concentrations of individual mAbs (see below).
Small aliquots of escape virus was harvested and frozen after each
passage at −80 °C. Escape viruses SARS-CoV 3C7 and SARS-CoV 4D4
were propagated in VeroE6 cells in the presence of 2EC50 of the
respective mAbs to maintain the escape mutant. Virus supernatant
was harvested after 48 h and frozen in 1 ml aliquots at −80 °C.
Expression of S proteins
The S1-Fc (Urbani) fragment used to examine mAb activity con-
sisted of amino acids 12–510. The constructs contain a C5 signalsequence and a human IgG Fc tag, lacking the transmembrane domain
(kind gift from Dr. Michael Farzan, Harvard University, (Wong et al.,
2004)). The S 12-510-Fc construct was transfected into 293T/T17 cells
using the CaPO3 method and puriﬁed by protein A sepharose beads
(Santa Cruz Biotechnology, Santa Cruz, CA) as described previously
(Coughlin et al., 2007).
Semiquantitation of inhibition of binding between S1 protein and
its receptor
Increasing concentrations of mAb were mixed with a constant
concentration (10 μg) of puriﬁed recombinant protein S12–510-Fc
and preincubated at 4 °C in the presence of 0.5% BSA for 1 h. Following
preincubation, the protein/mAb mixture was added to 2×105 VeroE6
cells and incubated at 4 °C for 1 h. Cells were washed two times with
0.5% BSA. Recombinant protein bound to the cell surface was detected
by ﬂow cytometry following staining with an FITC-labeled anti-
human IgG (BD Biosciences). Non-speciﬁc inhibition was evaluated
using an isotype control human IgG2b antibody (Zymed Laboratories,
San Francisco, CA).
Generation of pseudotyped virus
Pseudotyped virus was generated by co-transfection of 293T/T17
producer cells with HIV NL4–3.Luc.R-E- construct and pcDNA3.1-S
using Effectine transfection reagent according to the manufacturer's
instructions (Invitrogen, Carlsbad, CA). Pseudotyped virus allowed for
a single round infection. Pseudotyped virus was then used to infect
target 293T/T17 cells transiently transfected with ACE2 expression
plasmid (human ACE2 expression plasmid was a kind gift from Dr.
Michael Farzan).
Determination of post-binding inhibition
The HIV/S pseudovirus was bound to target 293T/T17 cells tran-
siently transfected with human ACE2 at 4 °C for 1 h, increasing
concentrations of mAb 4D4 were added and incubated at 37 °C
overnight (approximately 16 h). Subsequently, the medium was
replaced and 48 h post-infection luciferase expression was deter-
mined. The cells were lysed as per manufacturer's protocol (Promega,
Madison, WI) and the lysate mixed with luciferase reagent and read
using a luminometer. Simultaneously 4D4 was also used in a standard
entry inhibition assay as a positive control for determining the degree
of inhibition of pseudotyped virus entry.
Inhibition of pseudotyped virus entry
Entry inhibition of pseudovirus by standard neutralization was
performed by preincubating pseudovirus with mAbs at 37 °C for 1 h.
The pseudovirus/mAb mixture or pseudovirus alone was added to
target 293T/T17 cells transiently transfected with human ACE2
and incubated overnight at 37 °C (approximately 16 h) after which
media was replaced. Pseudotyped virus was quantitated by
p24 ELISA (ZeptoMetrix, Buffalo, NY). Following 48 h post-infection
cells were lysed and luciferase expression determined as described
above.
Generation of SARS-CoV escape mutants
VeroE6 cells were seeded at 1×104/well in a 96 well plate one
day prior to infection. The following day, 200TCID50 of SARS-CoV
(Urbani) was preincubated with each of eleven mAbs individually
(mAbs 6C1, 5D6, 4A10, 6C2, 5A5, 5E4, 3C7, 6B1, 3H12, 1B5, and
4D4) at concentrations of 1EC50, 1.5EC50, and 2EC50 for 1 h at 37 °C.
Subsequently, the virus/mAb mixture was added to VeroE6 cells
and incubated for 48 h at 37 °C. Following 48 h incubation cells
45M.M. Coughlin et al. / Virology 394 (2009) 39–46were examined visually for signs of CPE and virus supernatant
passaged in the presence of the mAbs individually at concentrations
of 1EC50, 1.5EC50, and 2EC50 for 1 h at 37 °C and added to VeroE6
cells plated the day before. Virus supernatant was passaged every
48 h for a total of nine passages.
Cell TiterGlo cell viability assay
The Cell TiterGlo Luminescent Cell Viability Assay (Promega,
Madison, WI) was used to measure CPE in VeroE6 cells, according to
the manufacturer's recommendations. This assay was used to
measure the neutralizing capacity of a combination of mAbs 4D4
and 3C7 using SARS-CoV (Urbani). Brieﬂy, 200TCID50 of SARS-CoV
(Urbani) was preincubated with mAbs 4D4 and 3C7 alone and in
combination at concentrations of mAb of 0.781, 0.391, and 0.195 μg/
ml and a standard microneutralization assay performed using VeroE6
cells plated one day earlier at 1×104 cells/well (Coughlin et al., 2007).
Following 48 h cell viability was measured as luminescence and
output expressed as relative luciferase units (RLU) using the Cell
TiterGlo Luminescent Cell Viability Assay.
Similarly, the escape viruses SARS-CoV 3C7 and SARS-CoV 4D4
were preincubated with a combination of mAbs (3C7, 3H12, and 4D4)
in a standard neutralization assay as described previously (Coughlin
et al., 2007). Following 48 h cell viability for the Cell TiterGlo
Luminescent Cell Viability Assay was measured as luminescence and
output expressed as relative luciferase units (RLU).
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